Cadence Pharmaceuticals (CADX) Reports a Q3 Loss
More News related to CADX
- Oppenheimer Downgrades Cadence Pharmaceuticals (CADX) to Perform
- Cadence Pharma (CADX) Dec volatility at 63, Feb at 111 into FDA goal date
- FDA Extends Cadence Pharmaceuticals (CADX) PDUFA Date by Three Months
- Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
- Cadence Pharmaceuticals (CADX) Up Ahead of Tomorrow's PDUFA Date
More News related to Earnings
- Shields & Co. Downgrades ALLETE, Inc. (ALE) to Hold
- Scotia Capital Downgrades Grupo Aeroportuario del Centro (OMAB) to Sector Perform
- Goldman Sachs Upgrades Bradesco and Banco do Brasil; Downgrades Bancolombia
- Wedbush Downgrades Burger King (BKC) to Underperform
- Morgan Stanley Upgrades Safeway (SWY), Downgrades SUPERVALU (SVU)
Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) reports a Q3 loss of $0.23, 4 cents better than the analyst estimate of ($0.27).
Related Categories
EarningsStocks Mentioned
+0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
